

1. Asiya Mahtab, Syed Arman Rabbani, Yub Raj Neupane, Shweta Pandey, Adil Ahmad, Mohd Ahmed Khan, Neha Gupta, Alka Madaan, Manu Jaggi, Nidhi Sandal, Harish Rawat, Mohd Aqil, Sushama Talegaonkar. Facile functionalization of Teriflunomide-loaded nanoliposomes with Chondroitin sulphate for the treatment of Rheumatoid arthritis. *Carbohydr Polym*, 2020 Dec 15;250:116926.
<https://pubmed.ncbi.nlm.nih.gov/33049840/>
2. Mishra H, Mishra PK, Iqbal Z, Jaggi M, Madaan A, Bhuyan K, Gupta N, Gupta N, Vats K, Verma R, Talegaonkar S. Co-Delivery of Eugenol and Dacarbazine by Hyaluronic Acid-Coated Liposomes for Targeted Inhibition of Survivin in Treatment of Resistant Metastatic Melanoma. *Pharmaceutics*. 2019 Apr 3;11(4). pii: E163. doi: 10.3390/pharmaceutics11040163.
<https://www.ncbi.nlm.nih.gov/pubmed/30987266>
3. Madaan A, Verma R, Singh AT, Jaggi M. Review of Hair Follicle Dermal Papilla cells as in vitro screening model for hair growth. *Int J Cosmet Sci*. 2018 Aug 25 (ahead of print).
<https://www.ncbi.nlm.nih.gov/pubmed/30144361>
4. Gupta A, Madaan A, Srivastava R, Kumar S, Sastry JLN. Evaluation of antioxidant, immunostimulatory and antifatigue properties of Dashmularishta using in vitro and in vivo assays. *Ind. J. Exp biol* 2018, 56(08):598-603.
<http://nopr.niscair.res.in/handle/123456789/44835>
5. Shraibom N, Madaan A, Joshi V, Verma R, Chaudhary A, Mishra G, Awasthi A, Singh AT, Jaggi M. Evaluation of in vitro anti-psoriatic activity of a novel polyherbal formulation by multiparametric analysis. *Antiinflamm Antiallergy Agents Med Chem*. 2017 16(2): 94 – 111.
<https://www.ncbi.nlm.nih.gov/pubmed/28730954>
6. Madaan A, Joshi V, Kishore A, Verma R, Singh AT, Jaggi M, Sung YK. In vitro Hair Growth Promoting Effects of Naringenin and Hesperetin on Human Dermal Papilla Cells and Keratinocytes. *American Journal of Dermatology and Venereology*. 2017 6(3): 51-57.
<http://article.sapub.org/10.5923.j.ajdv.20170603.02.html>
7. Pandit S, Kanjilal S, Awasthi A, Chaudhary A, Banerjee D, Bhatt BN, Narwaria A, Singh R, Dutta K, Jaggi M, Singh AT, Sharma N, Katiyar CK. Evaluation of herb-drug interaction of a polyherbal Ayurvedic formulation through high throughput cytochrome P450 enzyme inhibition assay. *J Ethnopharmacol*. 2017 Feb 2;197:165-172.
<https://www.ncbi.nlm.nih.gov/pubmed/27457692>
8. Gopalakrishna Pillai GK, Bharate SS, Awasthi A, Verma R, Mishra G, Singh AT, Jaggi M, Mithal A, Vishwakarma RA. Antidiabetic potential of polyherbal formulation DB14201: Preclinical development, safety and efficacy studies. *J Ethnopharmacol*. 2017 Feb 2;197:218-230.
<https://www.ncbi.nlm.nih.gov/pubmed/27457691>

9. Setia M, Meena K, Madaan A, Srikanth N, Dhiman K, Sastry JLN. In vitro Studies on Antidiabetic Potential of New Dosage Forms of AYUSH 82. *J Drug Res Ayur Sci* 2017 2(1): 1-9.
<http://www.jaypeejournals.com/eJournals/ShowText.aspx?ID=13448&Type=FREE&TYP=TOP&IN=eJournals/images/JPLOGO.gif&IID=1048&Value=55&isPDF=YES>
10. "Development of novel hair growth promoters addressing various forms of Alopecia" Oral presentation at 6th International Conference and Expo on Cosmetology, Trichology & Aesthetic Practices, April 13-14, 2017 Dubai, UAE. Singh AT, Unnithan JS, Madaan A, Verma R, Kumari S, Gupta N, Jaggi M.
11. "Development of novel products for improvement of skin health" Oral presentation at 6th International Conference and Expo on Cosmetology, Trichology & Aesthetic Practices, April 13-14, 2017 Dubai, UAE. Jaggi M, Madaan A, Verma R, Singh M, Gupta N, Gupta N, Singh AT.
12. "Development of a novel polyherbal topical formulation for the management of psoriasis". International Conference on Psoriasis and Skin Specialists Meeting, December 08-09, 2016 Dallas, USA. Jaggi M, Shraibom N, Madaan A, Verma R, Gupta N, Chaudhary A, Mishra G, Singh P, Dobhal S, Singh AT.
13. "ANTI-PSORIATIC POTENTIAL AND SAFETY OF A NOVEL POLYHERBAL FORMULATION" presented as eposter (P182) in 5th congress of the psoriasis international network, 7-9th July, 2016, Paris. Shraibom N, Madaan A, Verma R, Singh P, Kar R, Dobhal S, Chaudhary A, Mishra G, Awasthi A, Mookkan Jeyamurugan, T. Singh A., Jaggi M.
14. "DEVELOPMENT OF A NOVEL POLYHERBAL TOPICAL FORMULATION FOR THE MANAGEMENT OF ECZEMA" Oral presentation in 7th European Dermatology Congress, June 13-15, 2016, Alicante, Spain (DOI: 10.4172/2155-9554.C1.032). Singh AT, Shraibom N, Madaan A, Verma R, Chaudhary A, Mishra G, Singh P, Kar R, Dobhal S, T., Jaggi M.
15. "EVALUATION OF ANTI-PSORIATIC POTENTIAL OF A NOVEL POLYHERBAL FORMULATION BY MULTIPARAMETRIC ANALYSIS" Abstract ID: ATH16ABS-0416. eposter in 13th EADV Spring symposium, 19-22th May 2016, Athens, Greece. Shraibom N, Madaan A, Verma R, Joshi V, Meena K, Chaudhary A, Mishra G, Awasthi A, T. Singh A, Jaggi M.
16. Gupta A, Srivastava R, Setia M, Madaan A, Sastry JLN and Rai RK. Evaluation of Swarna Guggulu in management of arthritis basis in vitro anti-inflammatory efficacy and ingredient based benefits. *Annals of Phytomedicine* 2016 5(1): 35-39.
<http://ukaazpublications.com/attached/publications/35-39.pdf>
17. Madaan A, Verma R, Kumar V, Singh AT, Jain SK, Jaggi M. 1,8-Naphthyridine Derivatives: A Review of Multiple Biological Activities. *Arch Pharm (Weinheim)*. 2015 Dec;348(12):837-60.
<https://www.ncbi.nlm.nih.gov/pubmed/26548568>
18. Madaan A, Kanjilal S, Gupta A, Sastry JLN, Verma R, Singh AT, Jaggi M. Evaluation of immunostimulatory activity of Dabur Chyawanprash using in vitro assays. *Ind J Exp Biol*. 2015 Mar;53(03):158-63.
<https://www.ncbi.nlm.nih.gov/pubmed/25872246>

19. Kumar S, Madaan A, Verma R, Gupta A, Sastry JLN. In vitro anti-inflammatory effects of Mahanarayan oil formulations using dendritic cells based assay. *Annals of Phytomedicine* 2014 Dec;3(2): 40-45.
[http://ukaazpublications.com/attached/publications/article%20\(40-45\).pdf](http://ukaazpublications.com/attached/publications/article%20(40-45).pdf)
20. Cellular mechanisms mediating the anticancer activity of a novel polyherbal formulation. Nadav Menahem Shraibom, Manu Jaggi, Anu T Singh, Ritu Verma, Alka Madaan, Pratibha Singh, Anshumali Awasthi, Vidushi Joshi, Amitesh Kishore, Sheetal Dobhal, Ronodip Kar, Kalpana Meena. [Abstract #151470](#), American Society of Clinical Oncology (ASCO) 2015, Accepted for publication in JCO.
21. Evaluation of immunostimulatory activity of Chyawanprash using in vitro assays. Madaan A, Kanjilal S, Gupta A, Sastry JL, Verma R, Singh AT, Jaggi M. *Indian J Exp Biol*. 2015 Mar;53(3):158-63.
<http://www.ncbi.nlm.nih.gov/pubmed/25872246>
22. Hyaluronan coated liposomes as the intravenous platform for delivery of imatinib mesylate in MDR colon cancer. Negi LM, Jaggi M, Joshi V, Ronodip K, Talegaonkar S. *Int J Biol Macromol*. 2015 Feb;73:222-35.
<http://www.ncbi.nlm.nih.gov/pubmed/25478964>
23. Hyaluronic acid decorated lipid nanocarrier for MDR modulation and CD-44 targeting in colon adenocarcinoma. Negi LM, Jaggi M, Joshi V, Ronodip K, Talegaonkar S. *Int J Biol Macromol*. 2015 Jan;72:569-74.
<http://www.ncbi.nlm.nih.gov/pubmed/25220787>
24. Biodegradable polymeric nanoparticles for oral delivery of epirubicin: In vitro, ex vivo, and in vivo investigations. Tariq M, Alam MA, Singh AT, Iqbal Z, Panda AK, Talegaonkar S. *Colloids Surf B Biointerfaces*. 2015 Apr 1;128:448-56.
<http://www.ncbi.nlm.nih.gov/pubmed/25769281>
25. A stepwise procedure for isolation of murine bone marrow and generation of dendritic cells. Madaan A, Verma R, Singh AT, Jain SK, Jaggi M. *J Biol Methods* 2014 Vol 1, e1.
<http://www.jbmethods.org/jbm/article/view/12/6>
26. Surface engineered nanostructured lipid carriers for targeting MDR tumor: Part I. Synthesis, characterization and in vitro investigation. Negi LM, Talegaonkar S, Jaggi M, Verma AK, Verma R, Dobhal S, Kumar V. *Colloids Surf B Biointerfaces*. 2014 Nov 1;123:600-9.
<http://www.ncbi.nlm.nih.gov/pubmed/25454761>
27. Surface engineered nanostructured lipid carriers for targeting MDR tumor: Part II. In vivo biodistribution, pharmacodynamic and hematological toxicity studies. Negi LM, Talegaonkar S, Jaggi M, Verma AK, Verma R, Dobhal S, Kumar V. *Colloids Surf B Biointerfaces*. 2014 Nov 1;123:610-5.
<http://www.ncbi.nlm.nih.gov/pubmed/25454755>

28. 3D-QSAR study of benzotriazol-1-yl carboxamide scaffold as monoacylglycerol lipase inhibitors. Afzal O, Kumar S, Kumar R, Jaggi M, Bawa S. *J Pharm Bioallied Sci.* 2014 Oct;6(4):260-6.
<http://www.ncbi.nlm.nih.gov/pubmed/25400409>
29. A review on anticancer potential of bioactive heterocycle quinoline. Afzal O, Kumar S, Haider MR, Ali MR, Kumar R, Jaggi M, Bawa S. *Eur J Med Chem.* 2014 Jul 24. pii: S0223-5234(14)00651-5.
<http://www.ncbi.nlm.nih.gov/pubmed/25073919>
30. Addressing the potential toxicities of the non-specific P-glycoprotein modulation by amalgamation with targeted approach in MDR tumors. Negi LM, Jaggi M, Talegaonkar S. *Med Hypotheses.* 2014 Feb;82(2):240-2.
<http://www.ncbi.nlm.nih.gov/pubmed/24389106>
31. Development of protocol for screening the formulation components and the assessment of common quality problems of nano-structured lipid carriers. Negi LM, Jaggi M, Talegaonkar S. *Int J Pharm.* 2014 Jan 30;461(1-2):403-
<http://www.ncbi.nlm.nih.gov/pubmed/24345574>
32. Pharmacokinetic evaluation of C-3 modified 1,8-naphthyridine-3-carboxamide derivatives with potent anticancer activity: lead finding. Awasthi A, Lohani M, Singh MK, Singh AT, Jaggi M. *J Enzyme Inhib Med Chem.* 2014 Oct;29(5):710-21.
<http://www.ncbi.nlm.nih.gov/pubmed/24156741>
33. Sustained Release Cisplatin from a Microsphere Formulation Demonstrates Improved Safety and Efficacy in a Xenograft Bladder Cancer Rodent Model. Kamraj Mani, Vinod Sanna, Phillip Blaskovich, Xiao-Pei Guan, Ritu Verma, Archana Mathur, Howard Sard, Anu Singh, Manu Jaggi and Rachit Ohri, World Conference on Interventional Oncology (WCIO), May 11-14, 2014, New York City, NY, USA.
34. Cisplatin Microspheres Demonstrate Improved Cytotoxicity Profile against 6 Cancer Cell Lines. Bhanvi Mishra, Shekhar Dhokai, Ritu Verma, Phil Blaskovich, Xiao-Pei Guan, Archana Mathur, Howard Sard, Manu Jaggi, Anu Singh, Rachit Ohri. World Conference on Interventional Oncology (WCIO), May 16-19, 2013, New York City, NY, USA.
35. Pharmacokinetic evaluation of C-3 modified 1,8-naphthyridine-3-carboxamide derivatives with potent anticancer activity: lead finding; Anshumali Awasthi^{1,2}, Mohtashim Lohani², Manoj K. Singh¹, Anu T. Singh¹, and Manu Jaggi; *J Enzyme Inhib Med Chem*, Volume 29, 2014 - Issue 5.
<https://www.tandfonline.com/doi/abs/10.3109/14756366.2013.845817>
36. "in vitro screening tools to accelerate new drug discovery: Alternatives to animal testing" Best poster award at Ramanbhai Foundation 6th International Symposium -Advances in New Drug Discovery Technologies And Translational Research" held at Zydus Research Centre at Ahmedabad, India, 4th-6th Feb 2013. Madaan A, Joshi V, Verma R, Singh AT, Jaggi M.
http://www.rbfsymposium.net/Abstractbook_2013.pdf

37. A validated stability-indicating LC method for estimation of etoposide in bulk and optimized self-nano emulsifying formulation: Kinetics and stability effects. Akhtar N, Talegaonkar S, Khar RK, Jaggi M. Saudi Pharm J. 2013 Jan;21(1):103-11.
<http://www.ncbi.nlm.nih.gov/pubmed/23960824>
38. Self-nanoemulsifying lipid carrier system for enhancement of oral bioavailability of etoposide by P-glycoprotein modulation: in vitro cell line and in vivo pharmacokinetic investigation. Akhtar N, Talegaonkar S, Khar RK, Jaggi M. J Biomed Nanotechnol. 2013 Jul;9(7):1216-29.
<http://www.ncbi.nlm.nih.gov/pubmed/23909136>
39. Anti-inflammatory activity of a naphthyridine derivative (7-chloro-6-fluoro-N-(2-hydroxy-3-oxo-1-phenyl-3-(phenylamino)propyl)-4-oxo-1-(prop-2-yn-1-yl)-1,4-dihydro-1,8-naphthyridine-3-carboxamide) possessing in vitro anticancer potential. Alka Madaan, Vivek Kumar, Ritu Verma, Anu T. Singh, S.K. Jain, Manu Jaggi. International Immunopharmacology, Volume 15, Issue 3, March 2013, Pages 606–613.
<http://www.ncbi.nlm.nih.gov/pubmed/23370301>
40. Application of a liquid chromatography-electrospray mass spectrometry (LC/MS) method to the biodistribution and excretion studies of novel 5'-chloro-2, 3-didehydroindolo (2', 3': 2, 3) betulinic acid (DRF-4012) in tumour-bearing mice. Mishra G, Singh MK, Awasthi A, Singh AT, Jaggi M, Ahmad FJ. Xenobiotica. 2013 Jun;43(6):548-60.
<http://www.ncbi.nlm.nih.gov/pubmed/23256622>
41. Efficiency and mechanism of intracellular paclitaxel delivery by novel nanopolymer-based tumor-targeted delivery system, Nanoxel(TM). Madaan A, Singh P, Awasthi A, Verma R, Singh AT, Jaggi M, Mishra SK, Kulkarni S, Kulkarni H. Clin Transl Oncol. 2013 Jan;15(1):26-32.
<http://www.ncbi.nlm.nih.gov/pubmed/22855169>
42. Release-active dilutions of Diclofenac enhance anti-inflammatory effect of Diclofenac in Carrageenan-induced rat paw edema model. Sachin S. Sakat, Kamaraj Mani, Yulia O. Demidchenko, Evgeniy A. Gorbunov, Sergey A. Tarasov, Archana Mathur and Oleg I. Epstein. Inflammation Feb;37(1):1-9 (2014)
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3929039/pdf/10753_2013_Article_9705.pdf
43. LC–UV Detection of 5'-Chloro-2, 3-didehydroindolo (2', 3':2, 3) betulinic Acid in Rat Plasma and Its Application to a Pharmacokinetic Study. Gautam Mishra, Anshumali Awasthi, Manoj Kumar Singh, Manu Jaggi, Farhan J Ahmed. Chromatographia 2011; 73(3):281-289.
<http://link.springer.com/article/10.1007%2Fs10337-010-1862-9>
44. Evaluation of 5-hydroxy-2,3-diaryl (substituted)-cyclopent-2-en-1-ones as cis-restricted analogues of combretastatin A-4 as novel anti angiogenic and anticancer agents. Vinod Kumar Sanna, Manu Jaggi, Vadlapudi Kumar, Anand C Burman. Investigational New Drugs, 2010, 28(4):363-380.
<http://www.ncbi.nlm.nih.gov/pubmed/19424664>
45. Eclipta alba extract with potential for hair growth promoting activity." Kakali Datta, Anu T Singh, Ashok Mukherjee, Beena Bhat, B Ramesh and Anand C Burman. J Ethnopharmacol. 2009; 124(3):

46. 1,8-Naphthyridine-3-carboxamide derivatives with anticancer and anti-inflammatory activity. Kumar V, Jaggi M, Singh AT, Madaan A, Sanna V, Singh P, Sharma PK, Irchhaiya R, Burman AC. *Eur J Med Chem*. 2009 Aug;44(8):3356-62.
<http://www.ncbi.nlm.nih.gov/pubmed/19361894>
47. Anticancer and immunomodulatory activities of novel 1,8-naphthyridine derivatives". Kumar V, Madaan A, Sanna VK, Vishnoi M, Joshi N, Singh AT, Jaggi M, Sharma PK, Irchhaiya R, Burman AC. *J Enzyme Inhibition Med Chem*. 2009 Oct; 24(5):1169-78.
<http://informahealthcare.com/doi/abs/10.1080/14756360802696802>
48. Synthesis of 1-(2,6-dichlorophenyl)-3-methylene-1,3-dihydro-indol-2-one derivatives and in vitro anticancer evaluation against SW620 colon cancer cell line. Virsodia V, Manvar A, Upadhyay K, Loria R, Karia D, Jaggi M, Singh A, Mukherjee R, Shaikh MS, Coutinho EC, Shah A. *Eur J Med Chem* 2008 Jan 25, *Eur J Med Chem* Mar 2009; 44(3):1355-1362.
[doi:10.1016/j.ejmech.2008.01.012](https://doi.org/10.1016/j.ejmech.2008.01.012)
49. Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats. Bansal T, Mishra G, Jaggi M, Khar RK, Talegaonkar S. *Epub*. 2008 Dec 24. *Eur J Pharm Sci*. 2009 Mar 2; 36(4-5):580-90.
<http://www.ncbi.nlm.nih.gov/pubmed/19135530>
50. Modulation of key signal transduction molecules by a novel peptide combination effective for the treatment of gastrointestinal carcinomas. Anu T Singh*, Manu Jaggi, Sudhanand Prasad, Sarjana Dutt, Gurvinder Singh, Kakali Datta, Praveen R, Vinod K Sanna, Rama Mukherjee, Anand C Burman. *Investigational New Drugs* 2008;26(6):505-516.
<http://www.springerlink.com/index/a9vh625624m484km.pdf>
51. Anticancer activity of a peptide combination in gastrointestinal cancers targeting multiple neuropeptide receptors. Manu Jaggi, Sudhanand Prasad, Anu T Singh, Praveen R, Sarjana Dutt, Archana Mathur, Rajan Sharma, Neena Gupta, Rinku Ahuja, Rama Mukherjee, Anand C. Burman. *Investigational New drugs* 2008 Jan 24;26(6):489-504. <http://www.springerlink.com/index/743G8422HJ285120.pdf>
52. Protective effects of Terminalia arjuna against Doxorubicin-induced cardiotoxicity. Gurvinder Singh, Anu T. Singh, Aji Abraham, Beena Bhat, Ashok Mukherjee, Ritu Verma, Shiv K. Agarwal, Shivesh Jha, Rama Mukherjee, Anand C. Burman. *J Ethnopharmacol* 2008 Apr 17, *Epub* 2008 Feb 3; 117(1):123-9.
<http://www.ncbi.nlm.nih.gov/pubmed/18346858>
53. Pre-clinical evidence for altered absorption and biliary excretion of irinotecan (CPT-11) in combination with quercetin: possible contribution of P-glycoprotein. Bansal T, Awasthi A, Jaggi M, Khar RK, Talegaonkar S. *Life Sci*. 2008 Aug 15; 83(7-8):250-9.
<http://www.ncbi.nlm.nih.gov/pubmed/18619980>
54. Development and validation of reversed phase liquid chromatographic method utilizing ultraviolet detection for quantification of irinotecan (CPT-11) and its active metabolite, SN-38, in

rat plasma and bile samples: Application to pharmacokinetic studies. Tripta Bansal, Anshumali Awasthi, Manu Jaggi, Roop K. Khar, Sushama Talegaonkar. *Talanta*. Epub 2008 May 4, 2008 Sep 15; 76(5):1015-21.

<http://www.ncbi.nlm.nih.gov/pubmed/18761148>

55. Synthesis of functionalized amino acid derivatives as new pharmacophores for designing anticancer agents. Vivek Kumar; Mukesh M. Mudgal; Nidhi Rani; Amrita Jha; Manu Jaggi; Anu T. Singh; Vinod K. Sanna; Pratibha Singh; Pramod K. Sharma; Raghuvver Irchhaiya; Anand C. Burman. *J Enzyme Inhibition and Med Chem*. 2008 Aug 11:1

<http://www.informaworld.com/index/901490680.pdf>

56. Synthesis and cytotoxic activity of heterocyclic ring-substituted betulinic acid derivatives. Vivek Kumar, Nidhi Rani, Pawan Aggarwal, Vinod K. Sanna, Anu T. Singh, Manu Jaggi, Narendra Joshi, Pramod K. Sharma, Raghuvver Irchhaiya, Anand C. Burman. *Bioorg & Med Chem Lett*. 2008 Sep 15; 18(18):5058–5062

<http://www.ncbi.nlm.nih.gov/pubmed/18752941>

57. Pharmacological evaluation of C-3 modified Betulinic acid derivatives with potent anticancer activity. Rajendran P, Jaggi M, Singh MK, Mukherjee R, Burman AC. *Invest New Drugs* 2007 Sep 13, *Invest New Drugs* 2008; 26(1):25-34

<http://www.springerlink.com/index/RH4663740V635P60.pdf>

58. Synthesis and cytotoxic evaluation of 4/5-hydroxy-2,3-diaryl(substituted)-cyclopent-2-en-1-ones as cis-restricted analogues of combretastatin A-4. Mukund K. Gurjar§, Radhika D. Wakharkar*§, Anu T. Singh#, Manu Jaggi#, Hanumant B. Borate§, Ritu Verma#, Praveen R#, Sarjana Dutt#, Gurvinder Singh#, Vinod Sanna#, Manoj K. Singh#, Popat D. Shinde§, Vishal A. Mahajan§, Vinod H. Jadhav§, Kakali Dutta#, K Karthik#, Shiv K. Agarwal# and Rama Mukherjee *J Med Chem*. 2007 Apr 19, Epub 2007 Mar 21; 50(8):1744-53.

<http://www.ncbi.nlm.nih.gov/pubmed/17373779>

59. Bombesin analogs containing α -aminoisobutyric acid with potent anticancer activity. Sudhanand Prasad, Archana Mathur, Neena Gupta, Manu Jaggi, Anu T Singh, Praveen Rajendran, Vinod Sanna, Kakali Dutta and Rama Mukherjee. *J Pept Sci*. 2007 Jan; 13(1):54-62.

<http://www.ncbi.nlm.nih.gov/pubmed/17031871>

60. Substance P analogs containing alpha, alpha-dialkylated amino acids with potent anticancer activity. Prasad S, Mathur A, Jaggi M, Singh AT, Mukherjee R. *J Pept Sci* 2007; 13(8):544-8.

<http://www.ncbi.nlm.nih.gov/pubmed/17617800>

61. Delivering multiple anticancer peptides as a single prodrug using lysyl-lysine as a facile linker. Prasad S, Mathur A, Jaggi M, Mukherjee R. *J Pept Sci* 2007; 13(7):458-67.

<http://www.ncbi.nlm.nih.gov/pubmed/17559067>

62. Concurrent determination of topotecan and model permeability markers (atenolol, antipyrine, propranolol and furosemide) by reversed phase liquid chromatography: Utility in Caco-2 intestinal absorption studies, Bansal T, Singh M, Mishra G, Talegaonkar S, Khar RK, Jaggi M, Mukherjee R. *J Chromatogr B Analyt Technol Biomed Life Sci*. 2007 Oct 10, *J Chromatogr B*

Analyt Technol Biomed Life Sci. 2007 Nov 15, Epub 2007 Nov 1; 859(2):261-6.
<http://www.ncbi.nlm.nih.gov/pubmed/17936093>

63. Bombesin analogs containing alpha-amino-isobutyric acid with potent anticancer activity. Prasad S, Mathur A, Gupta N, Jaggi M, Singh AT, Rajendran P, Sanna VK, Datta K, Mukherjee R. *J Pept Sci* 2007; 13(1):54-62.
<http://www.springerlink.com/index/743G8422HJ285120.pdf>
64. Anticancer and anti-inflammatory activities of 1,8-naphthyridine-3-carboxamide derivatives. Srivastava SK, Jaggi M, Singh AT, Madaan A, Rani N, Vishnoi M, Agarwal SK, Mukherjee R, Burman AC. *Bioorg Med Chem Lett*. 2007 Dec 1, Epub 2007 Aug 11; 17(23):6660-4.
<http://www.ncbi.nlm.nih.gov/pubmed/17950602>
65. Octapeptide analogs of somatostatin containing α , α - dialkylated amino acids with potent anticancer activity. Sudhanand Prasad, Archana Mathur, Rajan Sharma, Neena Gupta, Rinku Ahuja, Manu Jaggi, Anu T. Singh and Rama Mukherjee. *American Peptide Symposia. Understanding Biology Using Peptides*; 2006 1(9): Part 8:639-640.
<http://www.springerlink.com/index/h7t15q7717350317.pdf>
66. Octapeptide analogs of Somatostatin containing α , α - Dialkylated amino acids with potent anticancer activity. Sudhanand Prasad, Archana Mathur, Rajan sharma, Neena Gupta, Rinku Ahuja, Manu Jaggi, Anu T. Singh & Rama Mukherjee. *International Journal of Peptide research & therapeutics* 2006 Jun 2006; 12(2):179-185.
www.springerlink.com/index/h7t15q7717350317.pdf
67. "Sesquiterpene Lactone Derivatives: Synthesis and their Cytotoxicity". Sanjay K. Srivastava, Manu Jaggi, Anu T. Singh, Aji Abraham, Shiv K. Agarwal, Rama Mukherjee and Anand C. Burman. *International conference on Advances in Drug Discovery Research (ISCBC) February 24-26, 2007 at Dr. Babasaheb Ambedkar Marathwada University, Aurangabad, India 2006 Aug 15*; 16(16):4195-4199.
[doi:10.1016/j.bmcl.2006.05.083](https://doi.org/10.1016/j.bmcl.2006.05.083)
68. Synthesis of 13-Amino Costunolide derivatives as Anticancer Agents. Sanjay K. Srivastava, Aji Abraham, Beena Bhat, Manu Jaggi, Anu T. Singh, Vinod K. Sanna, Gurbinder Singh, Shiv K. Agarwal, Rama Mukherjee and Anand C. Burman. *Bioorg. Med. Chem Lett*. 2006, 16:4195-4199.
<http://www.ncbi.nlm.nih.gov/pubmed/16766184>
69. Furanoid Sugar Amino Acids in Design of Analogs of VIP Receptor Binding Inhibitor. Sudhanand Prasad, Archana Mathur, Manu Jaggi, Rajan Sharma, Neena Gupta, Rama Mukherjee, Ajit C Kunwar and Tushar K Chakraborty. *Understanding Biology Using Peptides, Proceedings of the 19th American Peptide Symposium, 2005*; 661-662.
<http://www.springerlink.com/index/h16720np55851540.pdf>
70. DRF7295: A novel peptide based signal transduction modulator for the treatment of gastrointestinal carcinomas. Singh, AT, Jaggi, M, Prasad, S, Singh, G, Dutta, K, Rajendran, P, Burman, AC, Mukherjee, R. *Clin. Cancer Research* 2005; 11:9010S.

<http://www.ncbi.nlm.nih.gov/pubmed/18322652>

71. Anticancer activity of DRF7295: A peptide combination targeting multiple neuropeptide receptors in gastrointestinal cancers. Jaggi, M, Singh, AT, Prasad, S, Rajendran, P, Dutt, S, Burman, AC, Mukherjee, R. Clin. Cancer Research 2005; 11:9081S-9082S.
<http://www.ncbi.nlm.nih.gov/pubmed/18217205>
72. A Peptide Combination Targeting Multiple Neuropeptide Receptors for the Treatment of Gastrointestinal carcinomas. Manu Jaggi, Anu T. Singh, Sudhanand Prasad, Praveen R, Sarjana Dutt, Anand C. Burman, Rama Mukherjee. Anticancer Activity of DRF7295: Abstract accepted for the international Conference on Molecular targets and cancer therapeutics AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Philadelphia, Pennsylvania Nov 14 –18th 2005, Published in Clin. Cancer Res 2005 Dec 15; 11,24 (Suppl) abstract No .B198
<http://www.ncbi.nlm.nih.gov/pubmed/18217205>
73. A novel peptide based signal transduction modulator for the Treatment of Gastrointestinal carcinomas. Anu T. Singh, Manu Jaggi, Sudhanand Prasad, Gurvinder Singh, Kakali Datta, Praveen Rajendran, Anand C. Burman, Rama Mukherjee. DRF7295: Abstract accepted for Meeting on Molecular targets and cancer therapeutics AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Philadelphia, Pennsylvania Nov 14 – 18th 2005. Published in Clin. Cancer Res. Dec 15, 2005; 11, 24 (Suppl) Abstract No. A186.
<http://www.springerlink.com/index/a9vh625624m484km.pdf>
74. Octapeptide analogs of somatostatin containing α , α - di-alkylated amino acids with potent anticancer activity. Sudhanand Prasad, Archana Mathur, Neena Gupta, Manu Jaggi, Anu T Singh and Rama Mukherjee. Understanding Biology Using Peptides, Proceedings of the 19th American Peptide Symposium, 2005:639-640. International Journal of Peptide Research and Therapeutics 2006; 12(2):179-185.
<http://www.springerlink.com/index/F003254618603441.pdf>
75. Furanoid sugar amino acids as dipeptide mimics in design of analogs of vasoactive intestinal peptide receptor binding inhibitor. Prasad S, Mathur A, Jaggi M, Sharma R, Gupta N, Reddy VR, Sudhakar G, Kumar SU, Kumar SK, Kunwar AC and Chakraborty TK. J. Peptide Res. 2005; 66:75-84.
<http://www.ncbi.nlm.nih.gov/pubmed/16000121>
76. Synthesis of 3-O-acyl/3-benzylidene/3-hydrazone/3-hydrazine/17-carboxyacryloyl ester derivatives of betulinic acid as anti-angiogenic agents. Mukherjee Rama, Jaggi Manu, Rajendran Praveen, Srivastava Sanjay K, Siddiqui Mohammad JA, Vardhan Anand, Burman Anand C. Divisions of Experimental Oncology, Dabur Research Foundation, U.P., Ghaziabad, India. Bioorg & Med Chem Lett. 2004; 14(12):3169-3172. Publisher: Elsevier Science B.V., CODEN: BMCLE8 ISSN: 0960-894X. Journal written in English. CAN 141:123780 AN2004:403830 CAPLUS (Copyright (C) 2005 ACS on SciFinder (R)).
[doi:10.1016/j.bmcl.2004.04.010](http://dx.doi.org/10.1016/j.bmcl.2004.04.010)

77. Synthesis and cytotoxic activity of 3-O-acyl/3-hydrazine /2-bromo/20, 29-dibromo betulinic acid derivatives. Mukherjee Rama, Jaggi Manu, Siddiqui Mohammad JA, Srivastava Sanjay K, Rajendran Praveen, Vardhan Anand, Burman Anand C. Division of Experimental Oncology, Dabur Research Foundation, Ghaziabad, India. *Bioorg & Med Chem Lett.* 2004; 14(15):4087-4091. Publisher: Elsevier Science B.V., CODEN: BMCLE8 ISSN: 0960-894X. Journal written in English. CAN 141:225702 AN2004:523317 CAPLUS (Copyright (C) 2005 ACS on SciFinder (R)). <http://www.ncbi.nlm.nih.gov/pubmed/15225732>